共 281 条
[1]
Lin JJ(2017)Targeting ALK: precision medicine takes on drug resistance Cancer Discov 7 137-155
[2]
Riely GJ(2018)Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer J Clin Oncol 36 1199-1206
[3]
Shaw AT(2010)Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 1693-1703
[4]
Lin JJ(2013)Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2385-2394
[5]
Zhu VW(2013)CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study Lancet Oncol 14 590-598
[6]
Yoda S(2016)Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a Phase II Global Study J Clin Oncol 34 661-668
[7]
Yeap BY(2016)Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial Lancet Oncol 17 234-242
[8]
Schrock AB(2014)Ceritinib in ALK-rearranged non-small-cell lung cancer N Engl J Med 370 1189-1197
[9]
Dagogo-Jack I(2016)Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Lancet Oncol 17 452-463
[10]
Jessop NA(2015)Alternative transcription initiation leads to expression of a novel ALK isoform in cancer Nature 526 453-457